Source: Indian Pharma Post

Rising: Rising Pharma gets final approval from USFDA for Mesalamine Suppositories 1000 mg

The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million

Read full article »
Rising's Competitors | Rising's News | Rising's Financials
Stay up-to-date with the latest news on Rising
Est. Annual Revenue
$25-100M
Est. Employees
100-250
Vimal Kavuru's photo - President & CEO of Rising

President & CEO

Vimal Kavuru

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Rising